Globalpharma has secured an agreement for the production of new products lines from Polichem SA.

The conclusion of this agreement allows Globalpharma, through the transfer of a technology licence, to manufacture and distribute products for the treatment of respiratory tract conditions such as asthma, as well as gynaecology and immunity-related conditions.
Polichem is a private pharmaceutical company based in Lugano, Switzerland, with a long tradition of activity in the pharmaceutical field, having historical roots in Italy since 1947.  The company focuses on the development, registration, distribution and licensing of innovative pharmaceutical products, with its core business in the fields of gynaecology, dermatology, cardiovascular and the central nervous system.
Polichem licences and exports to four continents and more than 30 countries through its international network of partners. 80 per cent of sales are made in Europe and 20 per cent in the rest of the World.
Khalid Bin Kalban, managing director and CEO of Dubai Investments and chairman of Globalpharma, commented: “Polichem are well respected for creating new and exciting product lines based on their own in-house research programme.”
Abdelhamid Boutefah, area manger, Polichem, added, “The agreement is of great significance for Polichem, further strengthening our position outside of our core market, Europe.”
Dr Maged Amer, general manager, Globalpharma commented, “The strengthening of our product lines in Middle Eastern markets with the help of the Mackenzie & Stuart Group continues to be of key importance for Globalpharma. This technology provides us with the opportunity to penetrate into new markets such as Libya and Iraq with exciting new product offerings.”